Last update Jan. 17, 2021

νατεγκλινίδιο

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a meglitinide antidiabetic. It has a different structure from the sulfonylureas, but a similar mechanism of action. It induces endogenous insulin secretion and can cause hypoglycemia.
Nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients.
Oral administration, before meals, three times a day.

We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.

Its pharmacokinetic characteristics (very high plasma protein binding and a short half life) make it very unlikely its excretion into breast milk in significant amounts.

Diet, exercise, and breastfeeding improve blood sugar levels.


See below the information of this related product:

Alternatives

  • Glibenclamide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Hypocaloric Diet ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Insulin ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metformin Hydrochloride ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

νατεγκλινίδιο is Nateglinide in Greek.

Is written in other languages:

Group

νατεγκλινίδιο belongs to this group or family:

Tradenames

Main tradenames from several countries containing νατεγκλινίδιο in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 73 %
Molecular weight 317 daltons
Protein Binding 98 %
VD 0.14 l/Kg
pKa 4 -
Tmax 1 hours
1.5 hours

References

  1. Novartis. Nateglinide. Drug Summary. 2008 Full text (in our servers)

Total visits

703

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM